IP Library › Granted Patent US 7,498,161
Granted Patent B2
US 7,498,161 · App. 10/579,606 · Granted Mar 3, 2009

Mutant herpes simplex viruses comprising nucleic acid encoding a nitroreductase

Assignee: Crusade Laboratories Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,498,161
App. No.
10/579,606
Granted
Mar 3, 2009
Kind
B2
Abstract

An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy.

Claims (1)

1. The herpes simplex virus HSV1716/CMV-NTR/GFP deposited under ECACC accession number 03110501.

Assignments (3)
CHANGE OF NAME Recorded Jul 27, 2020
From: CRUSADE LABORATORIES LIMITED
To: VIRTTU BIOLOGICS LIMITED
Reel/Frame 053323/0007 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2006
From: BROWN, SUSANNE MOIRA
To: CRUSADE LABORATORIES LIMITED
Reel/Frame 017898/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2006
From: DUNN, PAUL
To: CRUSADE LABORATORIES LIMITED
Reel/Frame 017898/0173 →
Priority Claims (1)
GB 0326798.6 · Nov 17, 2003 · national
Continuity (1)
Related Publication 20070098689A1 · May 3, 2007